NCT07037199View on ClinicalTrials.gov

Efficacy and Safety of SHR-A1811 Followed by Dalpiciclib and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2030

Conditions
Advanced Breast Cancer
Interventions
DRUG

SHR-A1811 + dalpiciclib+ endocrine therapy

sequential SHR-A1811 followed by dalpiciclib plus endocrine therapy (fulvestrant or aromatase inhibitors)

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER